Clinical trials: First-line Therapy
- Condition First-line Therapy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Androgenetic Alopecia, Hair Loss
Low Level Light Device as a Primary Therapy for Androgenetic Alopecia
The purpose of this research is to study the safety and effectiveness of a light therapy device for human hair growth. This device, called the GENIX, is a type of cold, or non-heat producing light emitting diode (LED) that will…
- Conditions
- Androgenetic Alopecia, Hair Loss, Thinning Hair, Balding
- Trial name
- NCT04558242
- Testing
- Genix
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kiierr International, LLC
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Depression
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social…
- Trial name
- NCT04524598
- Testing
- Limbix Spark, Psychoeducation
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Limbix Health, Inc.
Alopecia
LLLT for Alopecia of the Eyebrow in Women
The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system…
- Trial name
- NCT04897555
- Testing
- LLLT
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Periorbital Wrinkles
Safety and Efficacy of XP200 Radiofrequency Treatment of Wrinkles
To evaluate the wrinkle-reducing effects of 3.25-MHz radiofrequency (RF) energy delivered in 4 weekly applications to human periorbital skin area by grating pre- and 90-days post treatment photographs on the Fitzpatrick Wrinkle…
- Trial name
- NCT01795417
- Testing
- RF XP200, XP200 RF device
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Locally Recurrent and Metastatic Breast Cancer
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment…
- Trial name
- NCT00511459
- Testing
- AMG 386, Bevacizumab, Paclitaxel
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Amgen